KEY POINTS
- This randomized multicenter study evaluated a mobile patient-reported outcomes system (mPROS) during curative-intent concurrent chemoradiotherapy for gastrointestinal, gynecological, lung, CNS, and head and neck malignancies. Between September 2022 and August 2023, 59 patients were randomized, with 55 completing at least one PROMIS-29 assessment: 28 assigned to mPROS and 27 to usual care. Only 46 patients completed both baseline and end-of-treatment assessments, compared with the original target enrollment of 114 patients.
- The intervention combined patient self-reporting with automated clinical alerts. Patients were encouraged to enter symptoms at least weekly using a smartphone application incorporating PRO-CTCAE questions. Symptoms worsening by ≥2 points or reaching a score of ≥3 on a 0–4 scale triggered email notifications to nursing or physician teams. The control group received standard assessments during scheduled on-treatment visits and routine clinical contact.
- Mobile symptom monitoring did not significantly improve physical quality of life at treatment completion. Mean PROMIS-29 physical-health change was −6.03 points with mPROS versus −4.04 points with usual care (p=0.45). Mental-health changes were similarly comparable at −2.82 versus −2.17 points (p=0.78). Multivariable models adjusting for demographic and clinical variables did not identify treatment assignment as a significant predictor of end-of-treatment physical (p=0.38) or mental (p=0.98) health scores.
- Quality-of-life differences remained inconclusive during early follow-up. At three months after treatment, only 35 patients completed the PROMIS-29 questionnaire, including 17 in the intervention group and 18 controls. Mean physical-health change from baseline was −6.63 with mPROS versus −2.89 with usual care, while mental-health change was −0.70 versus +0.94. These descriptive results do not demonstrate a recovery advantage with mobile monitoring.
- Patients engaged regularly with the application and reported numerous symptoms. Intervention participants used mPROS for an average of 43 days, submitting approximately 12 reporting sessions, or twice weekly. They recorded an average of 174 symptom attributes, including approximately 15 severe symptom attributes per participant. These findings demonstrate reporting activity but not necessarily that alerts produced clinically effective interventions.
- Patient satisfaction was high despite the absence of measurable quality-of-life benefit. Among 11 intervention participants completing exit assessments, mean ratings on a seven-point scale were 6.36 for feeling more involved in care, 6.27 for care-team understanding of symptoms, 6.18 for symptom tracking, and 6.09 for recommending the application. Clinicians described improved communication but also identified workflow demands and the need for integration with electronic health records.
- The trial was substantially underpowered and could not establish effects on acute healthcare utilization. The original design required 114 participants to detect the prespecified quality-of-life difference, but only 59 were enrolled. Acute hospital encounters were numerically more frequent in the intervention group, without a statistically significant difference. Patients also needed smartphone access and English proficiency, potentially excluding populations with greater digital or supportive-care needs.
CLINICAL TAKEAWAY
Mobile symptom self-reporting during curative chemoradiotherapy did not demonstrate improved physical or mental quality of life compared with usual care, despite favorable patient feedback and regular engagement. The findings suggest that collecting symptoms electronically is not sufficient to guarantee measurable clinical benefit without effective response pathways. However, the substantial recruitment shortfall and heterogeneous population prevent definitive conclusions about electronic monitoring effectiveness.